英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
030665查看　030665　在百度字典中的解释百度英翻中〔查看〕
030665查看　030665　在Google字典中的解释Google英翻中〔查看〕
030665查看　030665　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ‘My first symptoms of ovarian cancer’: Signs to look for and when to . . .
    A new memory jogger for ovarian cancer symptoms To learn more about ovarian cancer symptoms, as well as when to see a doctor, we consulted Jolyn Sharpe Taylor, M D , a surgeon who specializes in gynecologic cancers “Bloating, diarrhea and abdominal pain are three of the most common ovarian cancer symptoms,” Taylor explains
  • Mirvetuximab Soravtansine for Ovarian Cancer - WebMD
    Many people with epithelial ovarian cancer (EOC) respond to treatment at first But cancer comes back, or recurs, in up to 80% of those who get better Over time, a common treatment for advanced
  • Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
    Although people with advanced ovarian cancer can initially be treated successfully with platinum-based chemotherapy drugs, the cancer often comes back Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option
  • FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive . . .
    Mirvetuximab soravtansine-gynx is the first ADC approved for the treatment of ovarian cancer as well as the first targeted therapy approved for FRα-positive PROC Patients with PROC have limited treatment options, and there is an urgent need for safe and effective new therapies Mirvetuximab soravtansine-gynx was associated with a confirmed
  • Considering Elahere For Your Ovarian Cancer? Heres What . . . - SurvivorNet
    RELATED: Ovarian Cancer: Overview Platinum-based chemotherapies, such as cisplatin and carboplatin are a cornerstone of ovarian cancer treatment Far too often, however, these cancers can evolve and become resistant to these traditional medications Ovarian cancer is termed resistant when it returns within 6 months of treatment initiation
  • Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian . . .
    Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), a biomarker that is commonly overexpressed on ovarian carcinomas and
  • Mirvetuximab Shows Lasting Survival Benefit in Resistant Ovarian Cancer
    Mirvetuximab soravtansine-gynx (Elahere) continues to demonstrate superior overall survival (OS) and sustained clinical benefits vs investigator’s choice of chemotherapy (ICC) in patients with folate receptor α (FRα)–positive, platinum-resistant ovarian cancer, according to the final analysis of the phase 3 MIRASOL trial (NCT04209855) 1
  • First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve . . .
    This is the first antibody-drug conjugate with proven efficacy in ovarian cancer and the only approved biomarker-driven therapy for platinum-resistant ovarian cancer ” Mirvetuximab soravtansine is an antibody-drug conjugate targeting FR-alpha and conjugated to the highly potenttubulin inhibitor, DM4
  • 10 signs of ovarian cancer (and how to spot them)
    Desiree tells us that one promising development is Mirvetuximab; a new and innovative therapy that has shown improved survival rates in women with recurrent, platinum-resistant ovarian cancer Looking ahead, she says that artificial intelligence (AI) could transform ovarian cancer diagnosis and treatment AI-driven tools have the potential to:
  • ELAHERE® (mirvetuximab soravtansine-gynx) | HCP Website
    For patients with FRα +, platinum-resistant ovarian cancer, ELAHERE is the first treatment to show statistically significant improvements vs standard single-agent chemotherapy 1-3 * Median PFS: 5 6 months vs 4 0 months, P0 0001 † Median OS: 16 5 months vs 12 7 months, P=0 0046 ‡ ORR: 42% vs 16%, P0 0001 § View the Data





中文字典-英文字典  2005-2009